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Abstract
Background: Achromobacter xylosoxidans is increasingly being recognized as an emerging pathogen in cystic
fibrosis. Recent severe infections with A. xylosoxidans in some of our cystic fibrosis (CF) patients led to a
re-evaluation
of the epidemiology of CF-associated A. xylosoxidans infections in two Belgian reference centres (Antwerp and
Ghent). Several of these patients also stayed at the Rehabilitation Centre De Haan (RHC). In total, 59 A. xylosoxidans
isolates from 31 patients (including 26 CF patients), collected between 2001 and 2014, were studied. We evaluated
Matrix Assisted Laser Desorption Ionisation -Time of Flight mass spectrometry (MALDI-TOF) as an alternative for
McRAPD typing.
Results: Both typing approaches established the presence of a major cluster, comprising isolates, all from 21 CF
patients, including from two patients sampled when staying at the RHC a decade ago. This major cluster was the
same as the cluster established already a decade ago at the RHC. A minor cluster consisted of 13 isolates from
miscellaneous origin. A further seven isolates, including one from a non-CF patient who had stayed recently at the
RHC, were singletons.
Conclusions: Typing results of both methods were similar, indicating transmission of a single clone of A. xylosoxidans
among several CF patients from at least two reference centres. Isolates of the same clone were already observed at the
RHC, a decade ago. It is difficult to establish to what extent the RHC is the source of transmission, because the
epidemic strain was already present when the first epidemiological study in the RHC was carried out.
This study also documents the applicability of MALDI-TOF for typing of strains within the species A. xylosoxidans and
the need to use the dynamic cutoff algorithm of the BioNumerics® software for correct clustering of the fingerprints.
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Background
Non-fermentative Gram-negative bacilli belonging to
the genus Achromobacter are considered as worldwide
emerging bacteria in the cystic fibrosis (CF) population [1],
with a predominance of the species Achromobacter xylosox-
idans. This species can be found in diverse environments,
including hospitals [2]. Prevalence in different CF centres
varies, ranging from 3 to 30 % of the CF patients being
colonized with A. xylosoxidans [3–6]. According to the Bel-
gian CF registry, the prevalence of A. xylosoxidans in 2013
was 8.9 % in children and 12.2 % in adults.
Factors involved in the emergence of this microorganism
remain unknown [7], but are thought to result from select-
ive antimicrobial pressure and the survivor effect, together
with improved detection and identification methods.
Also, the clinical relevance of Achromobacter
colonization remains unclear [8]. In a study by Dunne, Jr.
& Maisch [9], the presence of A. xylosoxidans was associ-
ated with an exacerbation of pulmonary symptoms, but it
was difficult to determine the significance of this link
* Correspondence: Mario.Vaneechoutte@Ugent.be
1Laboratory Bacteriology Research (LBR), Department of Microbiology,
Immunology, and Clinical Chemistry, Faculty of Medicine and Health
Sciences, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cools et al. BMC Microbiology  (2016) 16:122 
DOI 10.1186/s12866-016-0736-1
because of concomitant isolation of Pseudomonas aerugi-
nosa. De Baets et al. [3] pointed to the possible clinical im-
portance of this species in CF, demonstrating that A.
xylosoxidans infects CF patients with more advanced lung
disease without affecting lung function decline. Others
demonstrated a lung function decline following infection
in a subset of patients with high antibody levels to A. xylo-
soxidans [10]. Several studies indicated an increased need
for antibacterial treatment [3, 11]. Otero et al. [12] estab-
lished that mean annual decline in lung function – mea-
sured as annual percentage loss of FEV1 (forced
expiratory volume in 1 s) was 2.49 % in nine patients
chronically colonized with A. xylosoxidans (compared to
1.27 % for intermittently colonized patients) and consid-
ered A. xylosoxidans as a major pathogen in CF, although
caution may be warranted because six of the patients were
also colonized with P. aeruginosa. Moreover, the level of
inflammation caused by Achromobacter xylosoxidans was
recently shown to be similar to that induced by Pseudo-
monas aeruginosa in chronically infected CF patients [10].
These authors determined cytokine levels in serum and
sputum for 11 CF patients colonized by only A. xylosoxi-
dans and compared these with those of 21 patients colo-
nized by only P. aeruginosa, 17 non-infected CF patients
and 11 healthy controls. A. xylosoxidans patients were
younger, but had a FEV1 decline similar to patients with
P. aeruginosa. A. xylosoxidans patients had significantly
higher sputum TNF-α compared to the other groups of
chronically infected patients. The authors concluded that
A. xylosoxidans can cause a level of inflammation similar
to P. aeruginosa in chronically infected CF patients and
should be considered and treated as a clinically important
pathogen in CF.
Little is known about the mode of transmission of A.
xylosoxidans among CF patients. Current knowledge will
be reviewed in more detail in the discussion.
Following some recent severe infections caused by A.
xylosoxidans among some of our CF patients [13], we de-
cided to determine the epidemiology of CF-associated A.
xylosoxidans in our two CF centres (Antwerp and Ghent)
and we compared the genotypes of the current isolates
with those of isolates collected during the period Septem-
ber 2001–October 2002 at the rehabilitation centre in De
Haan, where several CF patients from different centres
intermittently reside [14].
Methods
This study was approved by the ethical committee of the
Ghent University Hospital (2014/1133). All participants
signed informed consent.
Patients and strains
In total, 59 A. xylosoxidans isolates from 31 patients (of
which 26 CF patients), collected between 2001 and 2014,
were studied (Table 1). Fifty one A. xylosoxidans isolates
were from 26 CF patients, i.e. 39 isolates from 16 Ghent
University Hospital (GUH) patients, eight isolates from
7 Antwerp University Hospital (AUH) CF patients, and
four isolates from 3 CF patients collected at the time
they stayed at the Rehabilitation Centre at De Haan
(RHC), during the period September 2001–October
2002. Furthermore, we included eight epidemiologically
unrelated isolates: five isolates were from non-CF pa-
tients, i.e. four from patients at the GUH and one from
a non-CF patient that had stayed at the RHC recently,
and three isolates, including the type strain ATCC
27061T, were from culture collections.
Species identification by means of nrdA gene analysis
The nrdA gene, encoding the alpha subunit of the ribonucleo-
side diphosphate reductase, was amplified using primers
nrdA_F (5′-GAACTGGATTCCCGACCTGTTC-3′) and
nrdA_R (5′-TTCGATTTGACGTACAAGTTCTGG-3′) [15].
The reactions were performed in a final reaction mixture of
20 μl, containing 10 μl of FastStart PCR Master Mix (Roche
Applied Science, Basel, Switzerland), 0.2 μM of each primer,
and 2 μl of DNA template. Using a Veriti 96-well thermal
cycler (Applied Biosystems, Foster City, US), the following
PCR program was run: 94 °C for 5 min, three cycles of 45 s
at 94 °C, 2 min at 50 °C, 1 min at 72 °C, and 30 cycles of
20 s at 94 °C, 1 min at 50 °C and 1 min at 72 °C, with a final
extension at 72 °C for 7 min. After confirming the presence
of amplification products by electrophoresis on 2 % agarose
gels, stained with ethidiumbromide, DNA amplicons were
purified and sequenced at GATC Biotech (Cologne,
Germany) using nrdA_F as sequencing primer.
The obtained nrdA gene sequences were compared
with the Achromobacter nrdA sequences, available at
PubMLST: http://pubmlst.org.
McRAPD for strain typing
DNA was extracted from single colonies by alkaline lysis
as described before [16]. RAPD in combination with
melting curve analysis of amplified DNA fragments
(McRAPD) [17–19] was performed on a Lightcycler 480
(Roche Applied Science). The total reaction mixture per
sample was 20 μl and consisted of 2 μl of Lightcycler
FastStart DNA Master SYBR Green I (Roche Applied
Science), 0.5 mM of primer ERIC2 (5′- AAGTAAGT
GACTGGGGTGAGCG-3′), and 2 μl of DNA extract.
The PCR protocol started with an activation step of
10 min at 95 °C, followed by 55 cycles of denaturation at
95 °C for 30 s, annealing at 45 °C for 20 s and elongation
at 72 °C for 40 s. Melting down of the amplification
products started with 1 min at 75 °C followed by
increasing the temperature to 97 °C with a ramp rate of
0.1 °C/s. Fluorescence was measured continuously at
530 nm with six acquisitions per °C. The melting curves
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Table 1 Patients, isolates and typing results

















25 CF AUH 1 140923 Y N B I I 1
26 CF AUH 2-1 140923 Y Y B I I 1
35 CF AUH 2-2 140923 Y Y C I I 1
34 CF AUH 3 140923 Y Y C I I 1
2 CF AUH 4 140923 Y N A I I 1
36 CF AUH 5 140923 Y Y C I I 1
1 CF AUH 6 140923 N N A I I 1
3 CF AUH 7 140923 N Y A I I 1
27 CF GUH 002 020111 Y** Y B I I 1
45 CF GUH 004-1 120213 Y Y E II II 2
44 CF GUH 004-2 131015 Y Y E II II 2
48 CF GUH 004-3 131104 Y Y F II II 2
43 CF GUH 004-4 131206 Y Y E II II 2
41 CF GUH 004-5 140303 Y Y E II II 2
49 CF GUH 004-6 140303 Y Y F II II 2
57 CF GUH 014-1 131203 Y Y P1 P1 P1 P1
56 CF GUH 014-2 140204 Y Y P1 P1 P1 P1
6 CF GUH 020 140303 Y Y B I I 1
42 CF GUH 045 050825 N Y E II II 2
12 CF GUH 072-1 140328 Y N B I I 1
29 CF GUH 072-2 140408 Y N B I I 1
17 CF GUH 072-3 140408 Y N B I I 1
30 CF GUH 072-4 140429 Y N B I I 1
40 CF GUH 083 140204 N N D III I 1
58 CF GUH 086 Duplicate 1 140204 N N S3 S3 P2 P2
59 CF GUH 086 Duplicate 2 140204 N N S4 S4 P2 P2
15 CF GUH 088-1 131112 Y Y B I I 1
33 CF GUH 088-2 140106 Y Y B I I 1
14 CF GUH 088-3 140303 Y Y B I I 1
22 CF GUH 088-4 140328 Y Y B I I 1
24 CF GUH 088-5 140414 Y Y B I I 1
32 CF GUH 098-1 140106 Y Y B I I 1
18 CF GUH 098-2 140106 Y Y B I I 1
8 CF GUH 098-3 140328 Y Y B I I 1
10 CF GUH 098-4 140414 Y Y B I I 1
38 CF GUH 108-1 140204 Y N D III I 1
20 CF GUH 108-2 140409 Y N B I I 1
9 CF GUH 108-3 140414 Y N B I I 1
39 CF GUH 108-4 140422 Y N D III I 1
4 CF GUH 135 131104 Y N A I I 1
5 CF GUH 137 140303 Y Y B I I 1
13 CF GUH 139-1 140304 Y Y B I I 1
37 CF GUH 139-2 140303 Y Y D III I 1
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were calculated using the ‘Tm calling melting curve ana-
lysis’ from the LightCycler 480 Software (Roche Applied
Science). Interpretation of similarity of these simple pat-
terns was done by visual inspection by two interpreters.
MALDI-TOF mass spectrometry (MALDI-TOF)
Sample preparation
Strains were cultured for exactly 48 h on tryptic soy agar
plates + 5 % horse blood (Becton Dickinson, Erembode-
gem, Belgium) under aerobic conditions at 37 °C. A
bacterial suspension of McFarland seven was prepared
in 5 ml HPLC-grade water. A total of 300 μl of this sus-
pension was added to an Eppendorf tube containing 900
μl of ethanol 96 %. This suspension was centrifuged at
13,000 × g for 2 min, and the supernatant was discarded.
The centrifugation was repeated, and the residual etha-
nol was carefully aspirated and discarded. The pellet was
air dried and resuspended in 20 μl formic acid (70 %),
an equal volume of acetonitrile was added and the sus-
pension was centrifuged at 13,000 × g for 2 min.
MALDI-TOF for species identification
One μl cell-extract of each isolate was used for MALDI-
TOF MS based identification as described previously [16].
MALDI-TOF for strain typing
For each strain, MALDI-TOF spectra were generated of
eight spots of one μl-aliquots of cell extract as described
previously [20]. Spectra were generated by the FlexAnaly-
sis software (Bruker, Germany) and were exported as text
files. These raw spectra (.txt files) were subsequently
imported into the BioNumerics® software package 7.5
(Applied Biosystems, Sint-Martens Latem, Belgium).
Raw spectra were processed as follows: the baseline
was subtracted using a rolling disc algorithm with a disc
size of 50 points, the noise was computed using a Con-
tinuous Wavelet Transformation (CWT), and smoothing
was performed with a Kaiser digital filter using a moving
window with a window size of 20 points and beta of 10
points [21]. A second baseline subtraction was performed
using a rolling disc algorithm with a disc size of 200
points, and peaks were detected using a CWT with a sig-
nal to noise ratio of 20.
After processing, the eight raw MALDI-TOF mass
spectra obtained for each isolate were combined into
one composite mass spectrum (main spectrum, MSP) by
calculating the average signal intensity for each data
point of the eight technical replicates. Raw spectra with
a similarity lower than 95 % of the average of the raw
spectra were excluded from contribution to the MSP.
Cluster analysis and multidimensional scaling analysis
of MSPs
Two different types of analysis were performed on the
MSPs, i.e. cluster analysis based on a similarity matrix
and multi-dimensional scaling analysis.
Table 1 Patients, isolates and typing results (Continued)
31 CF GUH 172-1 131219 Y Y B I I 1
16 CF GUH 172-2 140303 Y Y B I I 1
19 CF GUH 172-3 140328 Y Y B I I 1
11 CF GUH 172-4 140401 Y Y B I I 1
7 CF GUH 186 131210 Y Y B I I 1
21 CF RHC 1 V-1 140407 Y** B I I 1
23 CF RHC 1 V-2 140415 Y** B I I 1
28 CF RHC 2 V 020402 Y* Y B I I 1
54 CF RHC 3S 010131 Y* Y S1 S1 S1 S1
47 NCF Coll 1 Type Before 1984 N NA B II II 2
50 NCF Coll 2 Unknown N NA B II II 2
53 NCF Coll 3 Unknown N NA B II II 2
52 NCF GUH 1 030520 N NA B II II 2
46 NCF GUH 2 031110 N NA B II II 2
51 NCF GUH 3 040924 N NA B II II 2
60 NCF GUH 4 030815 N NA S5 S5 S3 S3
55 NCF RHC 1 141204 Y NA S2 S2 S2 S2
Isolate designations: CF from cystic fibrosis patient, NCF from non-cystic fibrosis patient, AUH from patient from Antwerp University Hospital, GUH from patient
from Ghent University Hospital, RHC from patient when staying at the Rehabilitation Centre at De Haan (period: 2001–2002), Coll from culture collection of
Georges Wauters (Université Libre Bruxelles, Belgium), T type strain; −# numbering of different isolates from the same patient
Y*: Isolate from CF patient during his/her stay at the RHC, during the period 2001–2002. Affixes ‘S’ and ‘V’ indicate the clusters to which they had been assigned [14]
Y**: Recent isolate from a CF patient of which isolates were also collected during a previous stay (period 2001–2002) at the RHC [14], and for whom the isolates
were shown to belong to cluster V
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Cluster analysis based on a similarity matrix
For the cluster analysis, a similarity matrix was calcu-
lated using the curve-based Pearson product-moment
correlation coefficient and a similarity-based cluster was
constructed using the unweighted pair group method
with arithmetic mean (UPGMA) algorithm. In order to
try to delimit, by objective means, the relevant clusters
from the non-relevant clusters, a dynamic cutoff method
(the Cluster Cutoff method of the BioNumerics® software)
was used [22].
Briefly, this method draws a virtual line through the
dendrogram at a certain similarity level, and from the
resulting number of clusters defined by that line, a new,
simplified, similarity matrix is created, such that all
within-cluster values are 100 %, and all between-cluster
values are 0 %. Thereafter, the Point-biserial correlation,
i.e. the correlation between this new matrix and the ori-
ginal similarity matrix, is calculated. The level offering
the highest Point-biserial correlation is then considered
as the one offering groups most supported by the under-
lying data. As such, the BioNumerics® software allows
cutoff values to be different per cluster, i.e. dynamic
cutoff (BioNumerics® Manual, available upon request).
The in silico defined clusters were subsequently con-
sidered as true clusters and subjected to an automated
Jackknife test. The Jackknife method determines for each
MSP into which of the different defined clusters it matches
best by calculating the average or highest similarities of the
MSP with each cluster. In cases where a MSP has an
equally good match with a member of its own cluster and
a member of another cluster, the assignment of the
spectrum is spread equally between the two groups. The
obtained percentage of correct identifications is a measure
of the internal stability of that cluster [23].
Multi-dimensional scaling
(MDS) is a dimensionality reduction method, which is a
valuable alternative to the dendrogram methods, which
often oversimplify the data available in a similarity
matrix, and tend to produce overestimated hierarchies.
In contrast to dendrogram inferring methods, MDS does
not produce hierarchical structures, but instead pro-
duces 2D or 3D plots of the similarity matrix, in which
the spectra are spread according to their relatedness.
Results
Species identification by sequencing of the nrdA gene
indicated that all 59 isolates were A. xylosoxidans sensu
stricto and not one of the other recently described
Achromobacter species [15]. Also MALDI-TOF mass
spectrometry (MALDI-TOF), which has been shown to
be a reliable method for differentiation of the different
Achromobacter species [24], indicated that all isolates
were A. xylosoxidans sensu stricto.
Genotyping of the isolates by means of McRAPD indi-
cated the presence of two large groups (clusters I and II)
of closely related isolates (Table 1). Fig. 1 represents the
different McRAPD profiles that were observed. This
result was initially considered unreliable. Although the
largest cluster (cluster I) was backed up epidemiologi-
cally, as it consisted of isolates that were exclusively
from CF patients, cluster II comprised completely unre-
lated isolates, including the type strain ATCC 27061T.
Because cluster II was considered to be the result of lim-
ited discriminatory power of the McRAPD approach,
MALDI-TOF typing was introduced as an independent
approach for typing of these isolates. Table 1 presents
the MALDI-TOF result for each isolate. Figure 2 illus-
trates a comparison of the MSPs of two isolates, repre-
sentative for the two major clusters that were observed.
Clustering of the MSPs within the obtained dendrogram
(Fig. 3, Additional file 1: Figure S1) was interpreted inde-
pendently by three human observers and by the dynamic
cutoff method, available within the BioNumerics®
software. Interestingly, the human observers, using static
cut off lines, as indicated by the vertical lines in Fig. 3,
concluded that three large clusters (I - III, according to
interpreters 2 and 3) or even six clusters (A - F, according
to interpreter 1) were present, whereas the dynamic cutoff
algorithm indicated the presence of only two clusters (as
indicated by the bold tree lines).
Moreover, clustering obtained by means of the dynamic
cutoff algorithm was in complete agreement with the
McRAPD results, confirming the presence of only two
major clusters.
Also MDS analysis (presented in Fig. 4) confirmed
independently the presence of two clusters (cluster I
profiles: red dots, cluster II profiles: green dots) and the
separate position of the pairs and singletons (grey
colored points).
Finally, Jackknife analysis confirmed the presence of
only two clusters, because of 100 % correct assignation
of the individual MSPs to the clusters.
In summary, both McRAPD and MALDI-TOF typing
approaches established the presence of a major cluster
(cluster I), comprising isolates from CF patients only
(n = 21, 12 from GUH of which 11 had stayed at the
RHC, seven from the AUH of which five had stayed
at the RHC, and from two CF patients sampled when
staying at the RHC a decade ago). The isolates collected
from the two patients when these were at the RHC during
the period 2001–2002 have been shown to belong to a
major cluster (with ten patients), established at that time
at the RHC [14]. This indicates that the major cluster I,
established in this study, is the same as the major cluster
established at the RHC already more than a decade ago. A
minor cluster (cluster II) consisted of 13 isolates from
miscellaneous origin, i.e., three collection strains, seven
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Fig. 1 McRAPD profiles, representative for each of the clusters, pairs and singletons. a Clusters (I and II); b: Pairs (P1 and P2); c: Singletons (S1, S2 and S3)
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isolates from two CF patients of which one had stayed at
the RHC and three isolates from three non-CF GUH pa-
tients. A further two pairs of fingerprints (with one pair
containing two isolates of the same patient, P2) and three
singletons were observed. The singletons included the
non-CF patient that had stayed recently at the RHC (S2)
and one non-CF patient of the GUH (S1). One isolate,
representative for a smaller cluster of four patients at the
RHC during the period 2001–2002, was included in the
present study and was found to stand alone (S1).
Discussion
Background of the study
We decided to study the current epidemiology of the A.
xylosoxidans isolates from CF patients at two Belgian
reference centres (Antwerp (AUH) and Ghent (GUH)),
in response to recent cases of serious infections with A.
xylosoxidans [3]. More than a decade ago, we established
the presence of two clusters of genotypically strongly
similar isolates among ten (cluster V at the RHC) and
four patients (cluster S at the RHC), who stayed at the
RHC during the period September 2001–October 2002
[14]. At that time, A. xylosoxidans was still considered
as a rather innocuous colonizer of the CF airways. Since
then, several publications have caused an increased
awareness of the possible clinical importance of this spe-
cies, as has been briefly addressed in the introduction.
The source of the epidemic strain
The data from this study indicate that most CF patients
from the two centres seem to carry the same strain and
that this strain was already colonizing ten patients that
stayed at the RHC in the period 2001–2002. The large
cluster V of the RHC, comprising ten patients [14], cor-
responds with cluster I of this study. These data suggest
continued transmission of A. xylosoxidans between
Belgian CF patients, since more than 10 years. These
findings and the increasing knowledge of A. xylosoxi-
dans-associated morbidity over the following period led
to stringent segregation measures in our centres.
With regard to the question of the source of this large
and longlasting cluster, a single environmental source
seems unlikely. The RHC could have served as a source
for infection of several patients from different reference
centres with the same clone, but the data do not support
this possibility. First, at least two clusters (designated S
and V) were present already during the period 2001–
2002 among patients during their stay at the RHC.
Moreover, some CF patients, i.e. CF GUH 004 and CF
GUH 014, who have stayed at the RHC, did not carry
Fig. 2 Detailed comparison of two MALDI-TOF MS main spectra (MSPs). a Alignment of two MSPs, representative for cluster I (red, above) and
cluster II (blue, below). Spectrum range 2000–10000 m/z. b–c Enlargement of part of the spectrum (6000–7500 m/z): Gel view representation
(b) and peak view presentation (c). Only peaks with a central line are taken into account for comparison by the BioNumerics® software
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Fig. 3 (See legend on next page.)
Cools et al. BMC Microbiology  (2016) 16:122 Page 8 of 13
the cluster I strain, and some patients, who never stayed
at the RHC (CF AUH6, CF AUH7 and CF GUH 083),
carried the cluster I strain. A final argument against the
RHC as the source for this epidemic strain comes from
the non-CF patient who stayed recently at the RHC
(NCF RHC1), but who carries another strain.
It is difficult to establish to what extent this epidemic
spread is due to patient-to-patient transmission, also be-
cause most patients – four out of seven at the AUH and
11 out of 16 at the GUH – were co-colonized with P.
aeruginosa and therefore have been segregated from
each other for different periods.
We carried out intensive screening of the hospital
environment in the AUH, also during the stay of
patients, but could not isolate A. xylosoxidans at any
occasion, also not from the aerosol equipment.
Discriminatory power of McRAPD and genetic diversity of
A. xylosoxidans
The odd observation that several different isolates from
very different sources cannot be discriminated may be
due i) to close relatedness of these epidemiologically
unrelated isolates, ii) to limited discriminatory power of
McRAPD or to iii) limited genetic diversity within this
species. However, we assume that neither ii) nor iii) is
the case. Limited discriminatory power (ii) of McRAPD
cannot be the explanation, because this approach has
been shown to be discriminative for A. xylosoxidans and
other Gram-negatives [19], and especially because a
completely independent typing approach, i.e. MALDI-
TOF, leads to the same observation of limited diversity.
Also limited genetic diversity within this species (iii)
does not seem to be a valid explanation, because in this
study we established several different genotypes by two
independent techniques and because extensive genetic
diversity is also supported by e.g. the study of Amoureux
et al. [2], who observed 35 macrorestriction types among
50 environmental isolates. Therefore, we conclude that
the presence of only two types of A. xylosoxidans among
the set of isolates from CF patients indicates clonal
spread of only two strains of A. xylosoxidans strains
among these patients.
Comparison of our results with those of other
epidemiological studies
Establishment of chronic colonization/Predominance of strains
For several patients, we included different isolates,
collected over time spans between 1 (CF GUH 72) and
25 months (CF GUH 4). For all patients, we established
the presence of only one genotype, indicating that most
patients are colonized by only one predominant strain
over longer periods. This is in correspondence with
several other studies that have reported persistent
colonization of CF patients with A. xylosoxidans.
Chronic colonization has been established through the
persistence of the same clone/strain, whereby clonality
was established using diverse molecular typing methods
including macrorestriction analysis (PFGE), amplification
of repetitive bacterial sequences (rep-PCR) and randomly
amplified polymorphic DNA (RAPD) [2, 6, 25–27].
Achromobacter colonization of CF patients may be
transient, intermittent or chronic [28]. Initial colization
with A. xylosoxidans results in chronic colonization in
11 to 30 % of the CF patients [3, 4, 11].
Dunne, Jr. & Maisch [9] reported two CF patients, out
of eight, that were persistently colonized with A. xylosox-
idans, as documented by identical rep-PCR patterns for
strains repeatedly cultured from the patients. Vu-Thien
et al. [29] and Moissenet et al. [25] reported that eight of
the 120 children with CF, who were treated at the
Hôpital d’Enfants Armand-Trosseau (Paris) between
1990 and 1995, were persistently colonized with a single
strain of A. xylosoxidans, as documented by macrores-
triction analysis of subsequent isolates. Peltroche-
Llacshuanga et al. [30] reported two brothers with CF
with persistent airway colonisation with A. xylosoxidans.
Krzewinski et al. [31] used RAPD to genotype between
13 and 19 A. xylosoxidans isolates per patient for 15 pa-
tients. Thirteen of the 15 patients had a single genotype
identified. The other two patients each had an A-B-A
pattern, with a single intervening culture with a mark-
edly different genotype and reversion to the original
genotype in subsequent cultures. The overall conclusion
was that few patients carried more than one genotype of
A. xylosoxidans whereas for Stenotrophomonas malto-
philia and P. aeruginosa multiple genotypes per patient
(See figure on previous page.)
Fig. 3 UPGMA constructed tree, based on MALDI-TOF main spectra (MSPs) of 59 isolates (with isolate CF GUH 86–1 tested in duplo). At the left:
Clusters, Pairs (P) and Singletons (S). Tree lines indicated in bold refer to the clustering obtained by the BioNumerics® software on the basis of
MSPs. Isolate designations: CF from cystic fibrosis patient, NCF from non-cystic fibrosis patient, AUH from patient from Antwerp University Hospital,
GUH from patient from Ghent University Hospital, RHC from patient when staying at the Rehabilitation Centre at De Haan (period: 2001–2002),
Coll from culture collection of Georges Wauters (Université Libre Bruxelles, Belgium), T type strain; −# numbering of different isolates from the
same patient. Y*: Isolate from CF patient during his/her stay at the RHC, during the period 2001–2002. Affixes ‘S’ and ‘V’ indicate the clusters to
which they had been assigned [14]. Y**: Recent isolate from a CF patient of which isolates were also collected during a previous stay (period
2001–2002) at the RHC [14], and for whom the isolates were shown to belong to cluster V. At the right: Connector lines indicate some examples
whereby multiple isolates of the same patient are clustered differently according to whether the interpretation is done by human observers or by
the BioNumerics® software, i.e. patients CF AUH 2, CF GUH 4 and CF GUH 108
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were frequently observed. In accordance to Krzewinski
et al. [31], we also established – within the Belgian CF
population – that 64.5 % of the 76 P. aeruginosa-colo-
nized patients carried one, 26.3 % two and 9.2 % three P.
aeruginosa genotype(s) at the same time [32].
For the patient population at the CF rehabilitation
centre, we also found less genotypic diversity among the
A. xylosoxidans strains observed, compared with the P.
aeruginosa strains. Only two genotypes were present
among the 13 patients colonized with A. xylosoxidans
[14], and although we genotyped multiple A. xylosoxi-
dans colonies per patient, only one patient was found to
carry both types, whereas all others carried only a single
genotype. This again points to the predominant presence
of only a single strain per patient. Kanellopolou et al.
[33] recovered 34 A. xylosoxidans isolates from sputum
samples of nine cystic fibrosis patients at a cystic fibrosis
department for adults in Athens, Greece. Isolates that
Fig. 4 Multi-dimensional scaling (MDS), representing the MALDI-TOF main spectra (MSPs) of the isolates from Cluster I (red dots), Cluster II (green dots),
and the isolates not belonging to one of these clusters (grey dots). a Side view. b Top view
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were recovered repeatedly from each patient exhibited
identical macrorestriction profiles, indicating that the
same strain persisted in the lungs of all nine patients.
Magni et al. [26] showed a marked genetic relationship
between strains isolated from the same patients at differ-
ent times and Lambiase et al. [11] found, for six patients,
that sequential strains obtained in the study period from
the same patient showed identical macrorestriction
analysis profiles.
Otero et al. [12] considered nine out of the 18 adult A.
xylosoxidans-positive patients (mean age 26.6 years,
range 18–39 years) as chronically colonized.
Dupont et al. [1] documented intrapatient variability
and genome evolution, but this diversity was limited
compared to the large interpatient diversity, indicating
chronic colonization.
It should be noted that the group of Amoureux et al.
[6] did not reach this conclusion of limited genotypic di-
versity per patient. This may be due to a locally different
situation or due to the more discriminatory techniques
that were used by these authors. To resolve this
discongruence, isolates from different locations should
be studied with each other’s typing techniques.
In summary, most of the studies indicate that the same
strain of A. xylosoxidans can persist in the airways of CF
patients and that most patients are colonized by a pre-
dominant strain. This observation of limited diversity
per patient also enables to establish more easily whether
the same strain is present among different patients.
Co-colonization with P. aeruginosa
Patients colonized by A. xylosoxidans are frequently co-
colonized by P. aeruginosa. The six patients that were
followed up over a period of time in the study of
Lambiase et al. [11] were all co-colonized with P. aerugi-
nosa. Otero et al. [12] reported that ten out of 18
patients with A. xylosoxidans were co-colonized by P.
aeruginosa. Vu-Thien et al. [29] reported that six out of
the eight patients were co-colonized with P. aeruginosa.
In our previous study, we found that 11 of the 13 A.
xylosoxidans positive patients at the RHC were co-
colonized with P. aeruginosa [14]. In the present study,
15 out of the 23 CF-patients at the two reference centres
were co-colonized. In summary, co-colonization with P.
aeruginosa is frequently observed.
Comparison with epidemiology of A. xylosoxidans in CF
patients from other countries
The observation of this study that one A. xylosoxidans
strain can spread among several Belgian CF patients
corresponds to transmission reported in most other
studies, although epidemic strains have been reported
less frequently.
Dunne, Jr. & Maisch [9] found that all strains from
eight different patients were distinct between patients.
Moissenet et al. [25] found that two out of eight
colonized patients harbored the same strain. The two
patients colonized by the same strain had overlapping
periods of hospitalization and no common source was
identified, pointing to person-to-person spread.
Using macrorestriction analysis, Peltroche-Llacshuanga
et al. [30] reported identical isolates for the two brothers
with CF with persistent airway colonisation with A.
xylosoxidans.
Krzewinski et al. [31], using RAPD, found 92 A. xylo-
soxidans-positive CF patients from 46 US centres. There
were no cases of shared genotypes among different CF
centres. Of the seven centers with multiple A. xylosoxi-
dans-positive patients, five sites had patient pairs with
shared genotypes. Of these, two pairs were siblings, one
pair were friends who were frequently hospitalized at the
same time, and two were epidemiologically unrelated.
Kanellopolou et al. [33] recovered A. xylosoxidans
isolates from sputum samples of 71 CF patients at a CF
department for adults in Athens, Greece. Isolates from
five of the patients were genetically related.
In our previous study [14], carried out among 13 CF
patients, staying at the RHC and from whom A. xylosoxi-
dans could be isolated, two clusters were observed. The
largest cluster comprised ten patients, which was also
the size of the largest cluster of patients carrying P.
aeruginosa at the RHC at that time.
Raso et al. [4] used macrorestriction analysis to
characterize 42 A. xylosoxidans isolates obtained over
4 years from the respiratory tract of 22 CF patients from
Turin, Italy. The 31 typeable isolates were attributed to
eight distinct clusters. Lambiase et al. [11] found 53
patients (17.6 % of the total number of 300 patients
studied) that had at least one positive culture for A.
xylosoxidans and established, using macrorestriction
analysis, the presence of seven major clusters – compris-
ing between 3 and 9 strains.
Pereira et al. [34] recovered 122 A. xylosoxidans iso-
lates from two Brazilian CF reference centres over a 5-
year period from 39 patients. Isolates were genetically
heterogeneous between patients, but one genotype was
present in 56 % of the patients.
In a small study, with 13 Spanish CF patients, Barrado
et al. [35] found one pair of CF patients with genetically
identical A. xylosoxidans isolates.
Dupont et al. [1] found one pair of patients with re-
lated isolates, among 13 patients studied in Montpellier,
France.
Amoureux et al. [2, 6] collected, from 2011 to 2012,
339 samples in Dijon’s university hospital, in healthy
volunteers’ homes in the Dijon area, and in the outdoor
environment in Burgundy (soil, water, mud, and plants).
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A total of 50 strains of A. xylosoxidans were detected in
hospital (33 isolates), domestic (nine isolates), and
outdoor (eight isolates) samples, mainly in hand washing
sinks, showers, and water. Genotypic analysis and
blaOXA-114 sequencing revealed a wide diversity among
the isolates, with 35 macrorestriction analysis types and
18 variants of oxacillinases. Interestingly, ten isolates
from hospital environment were clonally related to
clinical isolates previously recovered from hospitalized
patients, and one domestic isolate was identical to one
recovered from a CF patient (not at the same house).
The strain recovered from a shower in the pneumology
department was clonally related to that recovered from
the sputum of a CF patient who had been chronically
colonized since 1995, but had not previously been hospi-
talized in that ward.
The usefulness of McRAPD and MALDI-TOF for typing of
Achromobacter xylosoxidans isolates
Our data indicate that McRAPD based genotyping and
MALDI-TOF based molecular phenotyping of 59 A.
xylosoxidans isolates are in perfect correspondence. This
confirms the usefulness of McRAPD for genotyping of
this and other Gram-negative species [19] and indicates
that MALDI-TOF is applicable not only for species
identification, but also for molecular typing.
The usefulness of the BioNumerics® software for
interpretation of the clustering within dendrograms
Interpretation of the clusters within a dendrogram by a
human observer is usually subjective and is based on a
single static threshold line. Apparently, it can be con-
cluded that the clustering reached by the BioNumerics®
dynamic cutoff algorithm is more reliable than the
interpretations by the human observers, for several
reasons. First, there is the complete agreement with the
McRAPD-based clustering, including the odd clustering
of a set of epidemiologically unrelated strains within
cluster II. Second, several isolates that were collected
from the same patients, and that were placed into differ-
ent clusters by the human interpreters, are clustered to-
gether by the dynamic cutoff method (see connector
lines to the right of Fig. 3, indicating isolates from the
same patient or duplicate fingerprints of the same
isolate). Third, regarding the seven fingerprints not
belonging to clusters I or II, all three human interpreters
concluded that there were five singletons and one pair of
related strains (P1), whereas the dynamic cutoff method
indicated three singletons and two pairs (P1 and P2), in
agreement with the McRAPD clustering. Again, the
software seems to reach a more reliable conclusion, also
because the two MALDI-TOF profiles, clustered in P2
by the software, were considered as representative for
two separate types by all three human observers,
whereas they actually represent two technical duplicates
of the same strain.
Conclusions
The clinical importance of A. xylosoxidans in CF pa-
tients has been recognized only recently. Although there
have been previous reports on shared genotypes of A.
xylosoxidans isolates among CF patients, the reported
patient clusters were of rather limited size, except for
the recent study from Brasil [34]. Here we report the
presence of an epidemic strain, colonizing most of the
A. xylosoxidans-positive patients in two Belgian CF
centres and show that it was present already more than
a decade ago among several CF patients attending the
Belgian rehabilitation centre at De Haan. As patient-to-
patient transmission is the most probable explanation
for the spread of this epidemic A. xylosoxidans strain, we
conclude that segregation measurements are mandatory.
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